Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Recruiting

Phase 3

Drug CombinationsComparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

Sponsor:

SWOG Cancer Research Network

Code:

NCT05561387

Conditions

Plasma Cell Myeloma

Eligibility Criteria

Sex: All

Age: 0+

Healthy Volunteers: Not accepted

Interventions

Bortezomib

Daratumumab and Hyaluronidase-fihj

Dexamethasone

Lenalidomide

Quality-of-Life Assessment

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-11-17. This information was provided to ClinicalTrials.gov by SWOG Cancer Research Network on 2025-06-04.